nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC
|
Navani, Neal |
|
|
205 |
C |
p. |
artikel |
2 |
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium
|
Naidu, Sindhu Bhaarrati |
|
|
205 |
C |
p. |
artikel |
3 |
Application of endobronchial ultrasound-guided cryobiopsy for centrally located intrapulmonary lesions: A retrospective cohort study
|
Nakai, Toshiyuki |
|
|
205 |
C |
p. |
artikel |
4 |
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
|
Di Lecce, Claudia |
|
|
205 |
C |
p. |
artikel |
5 |
Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer
|
Wu, Yongqing |
|
|
205 |
C |
p. |
artikel |
6 |
Burden and trends in subsequent primary lung cancer incidence by sex in the United States
|
Sung, Hyuna |
|
|
205 |
C |
p. |
artikel |
7 |
Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes
|
Abolfathi, Hanie |
|
|
205 |
C |
p. |
artikel |
8 |
Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study
|
Zhang, Minna |
|
|
205 |
C |
p. |
artikel |
9 |
Concerns about induction of autophagy: à propos of ibrilatazar
|
Rosell, Rafael |
|
|
205 |
C |
p. |
artikel |
10 |
Contents
|
|
|
|
205 |
C |
p. |
artikel |
11 |
Controlling nutritional status predicts postoperative survival and acute exacerbation in resected non-small cell lung cancer with interstitial lung disease
|
Matsubara, Taichi |
|
|
205 |
C |
p. |
artikel |
12 |
Corrigendum to “A Single-Centre Study on the Impact of Co-Mutations on Osimertinib Efficacy in EGFR-Mutated NSCLC” [Lung Cancer 200(Supplement 1) (February 2025) 108218]
|
Wyatt, Bethany |
|
|
205 |
C |
p. |
artikel |
13 |
Development and clinical validation of a prognostic algorithm for stroma-tumor ratio quantification in non-small cell lung cancer
|
Ahmad, Waleed K.M. |
|
|
205 |
C |
p. |
artikel |
14 |
Diagnostic accuracy of the Idylla™ mutation test for detecting EGFR mutations in non-small cell lung cancer: a meta-analysis
|
Pérez-Pérez, Manuel |
|
|
205 |
C |
p. |
artikel |
15 |
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
|
Fujisaki, Toshiya |
|
|
205 |
C |
p. |
artikel |
16 |
Effectiveness and safety of different wire types for preoperative localization of pulmonary nodules: A systematic review and meta-analysis
|
Zhang, Xiaowen |
|
|
205 |
C |
p. |
artikel |
17 |
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data
|
Gemelli, Maria |
|
|
205 |
C |
p. |
artikel |
18 |
Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors
|
Xie, Yuwen |
|
|
205 |
C |
p. |
artikel |
19 |
Geographic disparities in lung cancer screening uptake in the United States using the 2021 United States Preventive Services Task Force Guidelines
|
Gudina, Abdi T. |
|
|
205 |
C |
p. |
artikel |
20 |
Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis
|
George, Jinto Edakkalathoor |
|
|
205 |
C |
p. |
artikel |
21 |
Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases
|
Cheng, Sida |
|
|
205 |
C |
p. |
artikel |
22 |
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
|
Leighl, Natasha B. |
|
|
205 |
C |
p. |
artikel |
23 |
Lurbinectedin for extensive stage − small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes
|
Krayim, Belal |
|
|
205 |
C |
p. |
artikel |
24 |
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
|
Yan, Bo |
|
|
205 |
C |
p. |
artikel |
25 |
Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis
|
Yang, Ruiyuan |
|
|
205 |
C |
p. |
artikel |
26 |
Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis
|
Gawli, Chandrakant S. |
|
|
205 |
C |
p. |
artikel |
27 |
Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor
|
Iso, Hirokazu |
|
|
205 |
C |
p. |
artikel |
28 |
Revisiting margin adequacy in sublobar resection for pure ground-glass opacity adenocarcinomas
|
Kim, Ji Yong |
|
|
205 |
C |
p. |
artikel |
29 |
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
|
Zhang, Qian |
|
|
205 |
C |
p. |
artikel |
30 |
Targeting IDH2 promotes antitumor immunity through epigenetic activation of cGAS-STING pathway
|
Li, Jiang-jiang |
|
|
205 |
C |
p. |
artikel |
31 |
The prognostic impact of extra-alveolar invasion in lung adenocarcinoma
|
Suzuki, Masaki |
|
|
205 |
C |
p. |
artikel |